TAK1 Promotes an Immunosuppressive Tumor Microenvironment through Cancer-Associated Fibroblast Phenotypic Conversion in Pancreatic Ductal Adenocarcinoma
Blocking the TAK1+ CAF phenotype leads to the conversion of protumorigenic CAFs to antitumorigenic CAFs. This highlights TAK1 as a potential therapeutic target, particularly in CAFs, and represents a novel avenue for combined immunotherapy in PDAC.
Authors
- Taiki Moriyama (ORCID: https://orcid.org/0000-0001-7114-7040)
- Masafumi Nakamura (ORCID: https://orcid.org/0000-0002-6196-8643)
- Tomohiko Shinkawa
- Yoshinao Oda (ORCID: https://orcid.org/0000-0001-9636-1182)
- Naoki Ikenaga (ORCID: https://orcid.org/0009-0003-6285-6883)
- Kenoki Ohuchida (ORCID: https://orcid.org/0000-0003-4792-1168)
- Haimin Feng (ORCID: https://orcid.org/0000-0002-5718-4459)
- Koji Shindo (ORCID: https://orcid.org/0009-0007-6797-0289)
- Kohei Nakata (ORCID: https://orcid.org/0000-0002-5717-8569)
- Nan Sheng (ORCID: https://orcid.org/0009-0000-2458-3405)
- Takeo Yamamoto
- Bo Zhang
Institutions
- Kyushu University (JP)
- Fukuoka University (JP)
- Wuhan University (CN)
- Zhongnan Hospital of Wuhan University (CN)
Publication Details
- Journal
- Clinical Cancer Research
- Published
- 2024-09-12
- DOI
- https://doi.org/10.1158/1078-0432.ccr-24-1004
- Citations
- 16
- Primary Topic
- Cancer Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 6.18